Zerlasiran

Evidence outlook · lead readout

NCT05537571 · Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT05537571: The trial randomized participants to three zerlasiran regimens or placebo and masked both participants and investigators, with 180 participants enrolled. The primary endpoint was met for all active regimens, with statistically significant reductions in lipoprotein(a) versus pooled placebo; however, because the primary endpoint was a surrogate biomarker rather than a clinical outcome, this evidence is rated moderate.